DarioHealth Corp.
HealthcareNASDAQ:DRIO · NASDAQ Capital Market
-$0.14 today
Vol 0.00M · Avg 0.01M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$21.2M of revenue converted into $62.7M of net income for the selected period. Gross margin is 56.5% and net margin is 303.4%, showing how much revenue survives after costs and taxes. EPS is $2.25, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $22.4M -17.3% | $27.0M +32.9% | $20.4M -26.4% | $27.7M +34.8% | $20.5M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $9.7M -29.6% | $13.8M -4.1% | $14.4M -20.2% | $18.0M +44.7% | $12.4M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $12.7M -4.5% | $13.3M +121.7% | $6.0M -38.0% | $9.7M +19.7% | $8.1M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 56.6% +7.6pp | 49.1% +19.7pp | 29.4% -5.5pp | 34.9% -4.4pp | 39.3% | 9.8% | 28.9% | 38.3% |
| Research & Development | $13.8M -43.0% | $24.2M +19.4% | $20.2M +3.0% | $19.6M +14.1% | $17.2M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $35.5M -24.1% | $46.8M +12.0% | $41.8M -10.7% | $46.8M -24.9% | $62.4M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $49.3M -30.5% | $71.0M +14.2% | $62.2M -6.5% | $66.5M -21.4% | $84.6M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $3.6M -52.1% | $7.4M +49.0% | $5.0M +5.7% | $4.7M +5.8% | $4.5M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$34.7M +6.4% | -$37.1M +31.8% | -$54.4M +2.2% | -$55.6M +20.6% | -$70.0M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -155.2% -18.0pp | -137.1% +130.1pp | -267.2% -66.2pp | -201.0% +140.3pp | -341.3% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$36.7M +36.5% | -$57.7M -2.8% | -$56.2M +1.1% | -$56.8M +25.7% | -$76.5M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -163.9% +49.6pp | -213.6% +62.5pp | -276.1% -70.7pp | -205.4% +167.5pp | -372.9% | 16.6% | 24.1% | 22.0% |
| Interest Income | $943.0K -15.5% | $1.1M -40.3% | $1.9M +269.2% | $506.0K +1050.0% | $44.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $3.4M +3399.0% | $96.0K -85.1% | $645.0K -76.0% | $2.7M +3094.0% | $84.0K | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$5.0M -137.7% | $13.1M +514.1% | -$3.2M +41.0% | -$5.4M -2188.9% | -$235.0K | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$41.6M +6.7% | -$44.6M +24.9% | -$59.4M +4.5% | -$62.2M +18.9% | -$76.7M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -186.1% -21.2pp | -164.9% +126.7pp | -291.7% -66.8pp | -224.9% +149.2pp | -374.1% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $105.0K +105.7% | -$1.9M -2993.8% | $64.0K +1500.0% | $4.0K -87.5% | $32.0K | $1.3B | -$1.6B | $745.2M |
| Net Income | -$41.7M +2.4% | -$42.7M +28.1% | -$59.4M +4.4% | -$62.2M +19.0% | -$76.8M | $4.9B | $4.8B | $4.7B |
| Net Margin | -186.6% -28.5pp | -158.1% +133.9pp | -292.0% -67.1pp | -224.9% +149.3pp | -374.2% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $1 +267.6% | -$1 +61.7% | -$2 +26.6% | -$3 +43.2% | -$5 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $1 +267.6% | -$1 +61.7% | -$2 +26.6% | -$3 +43.2% | -$5 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $49.6M +22.8% | $40.4M +42.5% | $28.4M +20.0% | $23.6M +42.5% | $16.6M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $49.6M +22.8% | $40.4M +42.5% | $28.4M +20.0% | $23.6M +42.5% | $16.6M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
InnovAge Holding Corp.
NASDAQ:INNV
$1.24B
Avanos Medical, Inc.
NYSE:AVNS
$1.17B
Absci Corporation
NASDAQ:ABSI
$1.06B
Anbio Biotechnology Class A Ordinary Shares
NASDAQ:NNNN
$684.26M
Fulgent Genetics, Inc.
NASDAQ:FLGT
$530.52M
Myriad Genetics, Inc.
NASDAQ:MYGN
$408.96M
Pacific Biosciences of California, Inc.
NASDAQ:PACB
$406.89M
Orthofix Medical Inc.
NASDAQ:OFIX
$376.33M
REGENXBIO Inc.
NASDAQ:RGNX
$344.31M
Verastem, Inc.
NASDAQ:VSTM
$284.19M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does DRIO generate?
DarioHealth Corp. (DRIO) reported $22.36M of revenue in fiscal 2025.
Is DRIO profitable?
DarioHealth Corp. (DRIO) reported -$41,714,000.00 of net income, with a net margin of -186.6%.
Explore More
Continue the stock analysis
Jump to another research area for this company.